Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 6 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
Drug treatment may leads to lower primary outcome 2: Clinical recurrence at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).
1 finding from 1 review
Palpebral aperture change · thyroid‐associated ophthalmopathy
1 finding from 1 review
Motility · thyroid‐associated ophthalmopathy
1 finding from 1 review
Quality of life · thyroid‐associated ophthalmopathy
1 finding from 1 review
Adverse effects · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes CAS improvement (decrease) by 2 or more points compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 classes or more compared with placebo (very low certainty).
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
1 finding from 1 review
Growth · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbation frequency · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of treatment · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in adverse effects of treatment compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Eradication of MRSA · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
Oral plus nebulised antibiotics showed no clear difference in eradication of MRSA compared with oral antibiotics plus nebulised placebo (low certainty).
1 finding from 1 review
Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Add‐on stiripentol showed no clear difference in ≥ 50% reduction in seizure frequency compared with add‐on placebo (low certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Add‐on stiripentol showed no clear difference in seizure freedom compared with add‐on placebo (low certainty).
1 finding from 1 review
≥ 1 adverse effects · people with drug‐resistant focal epilepsy
Add‐on stiripentol may leads to higher ≥ 1 adverse effects compared with add‐on placebo (low certainty).
1 finding from 1 review